摘要
该文对桂枝茯苓胶囊及其15个活性成分组合物进行免疫调节活性评价,并对其作用机制进行初步探索。实验通过MTT法检测脾脏淋巴细胞体外增殖活化能力,观察桂枝茯苓胶囊及其活性成分组合物促淋巴细胞增殖作用;通过流式细胞术检测脾脏淋巴细胞中CD80/86,CD3CD25,CD3CD69的比例变化,评价桂枝茯苓胶囊及其活性成分组合物对脾脏淋巴细胞活化的影响。MTT结果显示400 mg·L-1的桂枝茯苓胶囊可以明显促进脾淋巴细胞的体外增殖,与对照组比较,差异具有统计学意义（P≤0.01）;15种活性成分组合物也具有相同的作用,在25~800 mg·L-1,与对照组比较,差异具有统计学意义（P≤0.01）,且在6.25~400 mg·L-1呈现明显的量效关系。流式细胞术结果显示400 mg·L-1桂枝茯苓胶囊与200 mg·L-1的15种活性成分组合物对脾淋巴细胞中CD80和CD86的表达均具有明显的促进作用;对CD3＋细胞中CD69和CD25的表达亦具有明显促进作用。综上,桂枝茯苓胶囊与其活性成分组合物具有一定的免疫调节活性,其机制可能与活化淋巴细胞密切相关。
The effects of Guizhi Fuling capsule and its active ingredient combination within different concentration on SPL proliferate were observed by MTT method. The ratio of CD80 /86,CD3CD25 and CD3CD69 was used to evaluate cell activation effects of Guizhi Fuling capsule and its active ingredient combination by FCM. Guizhi Fuling capsule with concentration of 400 mg·L-1can promote spleen lymphocyte proliferation,as well as the active ingredient combination,which showed the obvious dose-effect relationship.Compared with control group,the difference has statistical significance（ P≤0. 01）. The result of FCM showed that Guizhi Fuling capsule and its active ingredient combination can promote CD80 and CD86 expression on spleen lymphocyte,and also can increase CD25 and CD69 ratio between spleen CD3＋cells. Compared with control group,the difference has statistical significance（ P ≤ 0. 01）.Thus,Guizhi Fuling capsule and its active ingredient combination may have immune-modulate effects,and the mechanism may have a close relationship with the lymphocyte activation.
出处
《中国中药杂志》
CAS
CSCD
北大核心
2015年第15期3068-3071,共4页
China Journal of Chinese Materia Medica
基金
国家"重大新药创制"科技重大专项(2013ZX09402203)
关键词
桂枝茯苓胶囊
活性成分组合物
免疫调节活性
机制
Guizhi Fuling capsule
active ingredient combination
immune-modulation
mechanisms
